Outcomes and Treatment Sequences of Therapies with BCL2-and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

被引：2
|
作者：
Kutsch, Nadine [1 ,2 ,3 ]
Ligtvoet, Rudy [1 ,2 ,3 ]
Robrecht, Sandra [1 ,2 ,3 ]
Linde, Hartmut
Illmer, Thomas
Doerfel, Steffen [4 ]
Lipke, Joerg
Aldaoud, Ali
Schlag, Rudolf
Dengler, Jolanta
Al-Sawaf, Othman [1 ,2 ,3 ]
Langerbeins, Petra [1 ,2 ,3 ]
Cramer, Paula [1 ,2 ,3 ]
Eichhorst, Barbara F. [5 ]
Hallek, Michael [1 ,2 ]
Fischer, Kirsten [1 ,2 ,3 ]
Fink, Anna Maria [1 ,2 ,3 ]
机构：
[1] Univ Cologne, Fac Med, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany
[3] Univ Cologne, German CLL Study Grp, Cologne, Germany
[4] Ctr Oncol Dresden, Freiberg, Meissen, Germany
[5] Univ Cologne, Cologne, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185741
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Prognostic factors predicting disease progression in early (Binet stage A) chronic lymphocytic leukemia (CLL):: First analysis of the CLL1-protocol of the German CLL Study Group (GCLLSG).
    Schmitt, B
    Busch, R
    Kuhn-Hallek, I
    Bergmann, M
    Wendtner, CM
    Nerl, C
    Bosse, D
    Jäger, U
    Eckart, M
    Sezer, O
    Schmid, P
    Wilhelm, M
    Blau, I
    Döhner, H
    Hiddemann, W
    Emmerich, B
    Hallek, M
    BLOOD, 2000, 96 (11) : 371A - 371A
  • [22] Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Langerbeins, P.
    von Tresckow, J.
    Maurer, C.
    Kutsch, N.
    Lange, E.
    Kiehl, M.
    Fischer, K.
    Stilgenbauer, S.
    Wendtner, C-M
    Goede, V
    Hallek, M.
    Eichhorst, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 166 - 166
  • [23] Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Busch, Raymonde
    Renschler, Jasmin
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael J.
    Fink, Anna-Maria
    Kilp, Julia
    Ritgen, Matthias
    Boettcher, Sebastian
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    BLOOD, 2008, 112 (11) : 128 - 128
  • [24] Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).
    Fischer, Kirsien
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Renschler, Jasmin
    Busch, Raymonde
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael
    Fink, Anna M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Staib, Peter
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2007, 110 (11) : 913A - 914A
  • [25] Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)
    Fink, Anna
    Pflug, Natali
    Busch, Raymonde
    Fingerle-Rowson, Gunter R.
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Winkler, Dirk
    Buehler, Andreas
    Mendila, Myriam
    Wenger, Michael
    Dohner, Hartmut
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    BLOOD, 2010, 116 (21) : 404 - 405
  • [26] Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG)
    Al-Sawaf, Othman
    Robrecht, Sandra
    Bahlo, Jasmin
    Fink, Anna-Maria
    Cramer, Paula
    Maurer, Christian
    Bergmann, Manuela
    Dreyling, Martin
    Lange, Elisabeth
    Kneba, Michael
    Stilgenbauer, Stephan
    Jaeger, Ulrich
    Wendtner, Clemens
    Fischer, Kirsten
    Goede, Valentin
    Hallek, Michael
    Eichhorst, Barbara
    Hopfinger, Georg
    Doehner, Hartmut
    Kiehl, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 : 62 - 63
  • [27] Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL):: Results of two phase II studies (CLL2-protocol) of the german cll study group (GCLLSG).
    Hallek, M
    Wilhelm, M
    Emmerich, B
    Döhner, H
    Fostitsch, HP
    Sezer, O
    Herold, M
    Knauf, W
    Busch, R
    Schmitt, B
    Wendtner, CM
    Kuse, R
    Freund, M
    Franke, A
    Schriever, F
    Nerl, C
    Thiel, E
    Hiddemann, W
    Brittinger, G
    BLOOD, 1999, 94 (10) : 313A - 313A
  • [28] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG).
    Wendtner, CM
    Ritgen, M
    Schweighofer, CD
    Fingerle-Rowson, G
    Campe, H
    Jaeger, G
    Eichhorst, B
    Busch, R
    Diem, H
    Engert, A
    Stilgenbauer, S
    Doehner, H
    Kneba, M
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 676A - 676A
  • [29] Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group
    Simon, Florian
    Ligtvoet, Rudy
    Robrecht, Sandra
    Cramer, Paula
    Kutsch, Nadine
    Furstenau, Moritz
    Goede, Valentin
    von Tresckow, Julia
    Langerbeins, Petra
    Fink, Anna-Maria
    Huber, Henriette
    Tausch, Eugen
    Schneider, Christof
    Wendtner, Clemens-Martin
    Ritgen, Matthias
    Dreyling, Martin
    Mueller, Lothar
    Jacobasch, Lutz
    Heinz, Werner
    Vehling-Kaiser, Ursula
    Sivcheva, Liliya
    Boettcher, Sebastian
    Dreger, Peter
    Illmer, Thomas
    Gregor, Michael
    Staber, Philipp Bernhard
    Stilgenbauer, Stephan
    Niemann, Carsten Utoft
    Kater, Arnon P.
    Fischer, Kirsten
    Eichhorst, Barbara F.
    Hallek, Michael
    Al-Sawaf, Othman
    BLOOD, 2023, 142
  • [30] CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP
    Al-Sawaf, O.
    Bahlo, J.
    Fischer, K.
    Herling, C.
    Hoechstetter, M.
    Fink, A.
    von Tresckow, J.
    Langerbeins, P.
    Cramer, P.
    Stilgenbauer, S.
    Wendtner, C.
    Eichhorst, B.
    Hallek, M.
    Goede, V.
    HAEMATOLOGICA, 2017, 102 : 421 - 421
12345